Lead Product(s) : VNA-052
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Eurostars
Deal Size : $1.1 million
Deal Type : Financing
TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA
Details : Through financing, Vandria will be focusing on the mitophagy drug candidate VNA-052 to generate pre-clinical data in Vandria’s muscle program for the treatment of sporadic inclusion body myositis.
Product Name : VNA-052
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 02, 2024
Lead Product(s) : VNA-052
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Eurostars
Deal Size : $1.1 million
Deal Type : Financing
Lead Product(s) : ISB 880
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Almirall
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Almirall is granted global rights to develop and commercialize ISB 880, monoclonal antibody for autoimmune diseases. Ichnos will retain rights for antibodies acting on the IL-1RAP pathway for oncology indications.
Product Name : ISB 880
Product Type : Antibody
Upfront Cash : $23.6 million
December 14, 2021
Lead Product(s) : ISB 880
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Almirall
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : PN-1007
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Polyneuron’s PN-1007 Receives U.S. FDA Orphan Drug Designation in Anti-MAG Neuropathy
Details : In a dose titration study in mice, intravenous administration of PN-1007 was able to efficiently remove all anti-MAG IgM antibodies, strongly supporting the anticipated effective dose range for the upcoming phase I/IIa study in patients.
Product Name : PN-1007
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 06, 2020
Lead Product(s) : PN-1007
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PN-1007
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Polyneuron Receives Approval to Begin Clinical Study With PN-1007 in Anti-MAG Neuropathy
Details : Regulatory authorities in France, the Netherlands and the UK have approved the clinical trial application for a phase I/IIa study of PN?1007 for the treatment of anti-MAG neuropathy.
Product Name : PN-1007
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 27, 2020
Lead Product(s) : PN-1007
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable